Status:
COMPLETED
Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)
Lead Sponsor:
Lu Jiang
Conditions:
Caffeine
Burning Mouth Syndrome
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The aim of this study was to evaluate the efficacy of caffeine and alpha-lipoic acid in the treatment of burning mouth syndrome by symptom assessment with visual analogue scale.
Detailed Description
The etiology of BMS is multifactorial, involving a complex interplay of neuropathic, psychological, neuroendocrine, and immunological factors. Neurologically, BMS has been categorized into three subty...
Eligibility Criteria
Inclusion
- Adults over 18 years of age
- Diagnosis of BMS according to the 3rd edition of the International Classification of Headache Disorders (ICHD-3)
- Daily intraoral burning or dysaesthesia lasting for more than 2 hours for over 3 months
- Normal oral mucosa and sensory testing
- Condition not better accounted for by another ICHD-3 diagnosis
Exclusion
- Secondary BMS due to local or systemic disorders
- Prior treatment for BMS
- Psychiatric or progressive neurological disorders
- Systemic disorders potentially associated with oral disease
- Long-term history of smoking, drinking, or medication use
- Consumption of caffeinated products
- Poor oral hygiene
- Abnormal blood test results (including blood count, glucose, serum iron, ferritin and transferrin, folic acid, or vitamin B12 levels)
- Incomplete medical records
- Unwillingness to participate
Key Trial Info
Start Date :
December 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 23 2023
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT06195137
Start Date
December 13 2021
End Date
June 23 2023
Last Update
January 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital of Stomatology, Sichuan University
Chengdu, China, 610041